Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 ...

Cynata Therapeutics completes patient enrolment in phase 2 trial of CYP-001 in adults with newly diagnosed, high risk aGvHD: Melbourne, Australia Tuesday, December 16, 2025, 14:00 ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...

Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...

Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its ...

“To provide menstruating patients with sickle cell disease the best care, primary care physicians, gynecologists, and ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that ...

Company plans to discuss results and regulatory pathway of IGV-001 with U.S. FDA in the coming months -- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole ...